<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02856750</url>
  </required_header>
  <id_info>
    <org_study_id>16-1170</org_study_id>
    <nct_id>NCT02856750</nct_id>
  </id_info>
  <brief_title>Efficacy of Gabapentin vs. Placebo for Adjuvant Pain Control Following Acute Rib Fractures</brief_title>
  <official_title>A Multicenter, Randomized Controlled Trial of the Efficacy of Gabapentin vs. Placebo for Adjuvant Pain Control Following Acute Rib Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Denver Health and Hospital Authority</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Denver Health and Hospital Authority</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multi-center, Randomized Controlled Trial of the Efficacy of Gabapentin vs. Placebo for
      Adjutant Pain Control Following Acute Rib Fractures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Traumatic rib fractures are a tremendous source of pain which can limit respiratory function
      and overall recovery. Numerous multimodal pain management strategies have been employed with
      varying success; however, narcotics remain the mainstay of treatment. Beyond the acute side
      effects of narcotics, including altered mental status, depression of respiratory drive, and
      constipation, there is a substantial risk of long term dependency. Recently, loco-regional
      blockade and non-narcotic adjuncts have received increasing support within the literature.
      Gabapentin has been used extensively as a non-narcotic adjunct to analgesia regimens in the
      acute and chronic settings, however its ability to better control pain secondary to traumatic
      rib fractures has never been studied .

      The primary aim is to assess the efficacy of gabapentin as an analgesic after rib fractures.
      Secondary aims are to assess the effect on pulmonary function and other known complications
      following rib fractures.

      The hypothesis is gabapentin will improve pain control as measured by lower pain scores and
      lower narcotic needs. The investigators plan to test this hypothesis by recruiting trauma
      patients with rib fractures, and randomly assign them to gabapentin versus a placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Daily Pain Score</measure>
    <time_frame>30 days</time_frame>
    <description>the pain score uses the visual analog scale and ranges from 0 to 10. This is recorded by nursing at pre-specified intervals depending on level of care.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Narcotic requirements</measure>
    <time_frame>30 days</time_frame>
    <description>measurement of daily narcotic use as 24 hour requirements of morphine equivalents, and duration of narcotic needs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulmonary function</measure>
    <time_frame>30 days</time_frame>
    <description>assessment of the incidence of pneumonia (defined clinically by the treatment team), the incidence of hypoxemia, as well as readmission for pulmonary compromise.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gabapentin 300 mg three times daily x 30 d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no gabapentin administered to this arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Gabapentin 300 mg three times daily x30 days</description>
    <arm_group_label>gabapentin</arm_group_label>
    <other_name>neurontin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 1 rib fractures

          -  Requiring hospital admission

          -  Enrolled within 24 hours of injury

        Exclusion Criteria:

          -  Pregnancy

          -  Intubation

          -  Age &lt;18, age &gt;65

          -  Inability to tolerate PO medication

          -  Patient refusal

          -  Inability to obtain consent from patient or surrogate

          -  Renal or Hepatic impairment

          -  Allergy or Hypersensitivity to gabapentin or any component of the formulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fredric M Pieracci, MD, PMPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Denver Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederic Pieracci, MD, MPH</last_name>
    <phone>3034363000</phone>
    <email>frederic.pieracci@dhha.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eliza Moskowitz, MD</last_name>
    <phone>3038074448</phone>
    <email>eliza.moskowitz@ucdenver.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Denver Health Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredric M Pieracci, MD, MPH</last_name>
      <phone>303-436-4029</phone>
      <email>fredric.pieracci@dhha.org</email>
    </contact>
    <contact_backup>
      <last_name>Maria Rodil, BA</last_name>
      <phone>303-602-3793</phone>
      <email>maria.rodil@dhha.org</email>
    </contact_backup>
    <investigator>
      <last_name>Fredric M Pieracci, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Rodil, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eliza E Moskowitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ernest E Moore, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Scott Moore, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franklin L Wright, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Goodman, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jim Haenel, CRT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sirmali M, Türüt H, Topçu S, Gülhan E, Yazici U, Kaya S, Taştepe I. A comprehensive analysis of traumatic rib fractures: morbidity, mortality and management. Eur J Cardiothorac Surg. 2003 Jul;24(1):133-8.</citation>
    <PMID>12853057</PMID>
  </reference>
  <reference>
    <citation>Chapman BC, Herbert B, Rodil M, Salotto J, Stovall RT, Biffl W, Johnson J, Burlew CC, Barnett C, Fox C, Moore EE, Jurkovich GJ, Pieracci FM. RibScore: A novel radiographic score based on fracture pattern that predicts pneumonia, respiratory failure, and tracheostomy. J Trauma Acute Care Surg. 2016 Jan;80(1):95-101. doi: 10.1097/TA.0000000000000867.</citation>
    <PMID>26683395</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
    <mesh_term>Rib Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

